Literature DB >> 11049798

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

S Sundar1, D K More, M K Singh, V P Singh, S Sharma, A Makharia, P C Kumar, H W Murray.   

Abstract

In India, 320 patients with visceral leishmaniasis (209 in the state of Bihar and 11 in the neighboring state of Uttar Pradesh) received identical pentavalent antimony (Sb) treatment. Sb induced long-term cure in 35% (95% confidence interval [CI], 28%-42%) of those in Bihar versus 86% (95% CI, 79%-93%) of those in Uttar Pradesh. In Bihar, the center of the Indian epidemic, traditional Sb treatment should be abandoned.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11049798     DOI： 10.1086/318121

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  187 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Leishmaniasis: new approaches to disease control.

Authors:  Clive R Davies; Paul Kaye; Simon L Croft; Shyam Sundar
Journal:  BMJ       Date:  2003-02-15

3.  The economic value of a visceral leishmaniasis vaccine in Bihar state, India.

Authors:  Bruce Y Lee; Kristina M Bacon; Mirat Shah; Sara Beth Kitchen; Diana L Connor; Rachel B Slayton
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

4.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

5.  Identification of new antileishmanial leads from hits obtained by high-throughput screening.

Authors:  Xiaohua Zhu; Trupti Pandharkar; Karl Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

6.  Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Authors:  Prabhat K Sinha; Paul Roddy; Pedro Pablo Palma; Alice Kociejowski; María Angeles Lima; Vidya Nand Rabi Das; Jitendra Gupta; Nawin Kumar; Gaurab Mitra; Jean-François Saint-Sauveur; Siju Seena; Manica Balasegaram; Fernando Parreño; Krishna Pandey
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

7.  A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.

Authors:  Nawin Kumar; Prabhat Kumar Sinha; Krishna Pandey; Neena Verma; Chandra Shekhar Lal; Alok Ranjan; Rakesh Bihari Verma; Pradeep Das
Journal:  Int J Clin Pharm       Date:  2011-07-22

Review 8.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

9.  Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Authors:  Vasundhra Bhandari; Shyam Sundar; Jean Claude Dujardin; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.